With a market cap of $9.1 billion, Viatris Inc. (VTRS) is a global healthcare company with a portfolio of over a thousand ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

The nasal spray, dubbed neffy, has been filed for use in adults and children weighing 30 mg or more as an alternative to epinephrine injections such as Kaléo’s AUVI-Q and Viatris’ EpiPen ...

Viatris will spend as much as $335 million to settle opioid-related claims against the Canonsburg-based pharmaceutical company. The proposed settlement over nine years would come in the form of ...

Viatris (NASDAQ:VTRS) has agreed to pay up to a maximum of $335M as part of a nationwide settlement to resolve opioid-related claims. The amount consists of annual payments over a nine-year period ...

Learn more about whether Ligand Pharmaceuticals Incorporated or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

PITTSBURGH, April 25, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, will present at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV, on Tuesday ...

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a former Pfizer division. Headquartered in ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the ...

Viatris (VTRS, Financials) will pay up to $335 million in annual installments over nine years to settle opioid-related claims from U.S. states, local governments, and tribal entities, the company ...